{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:14:39Z","timestamp":1783487679749,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014732","name":"Neurofibromatosis Therapy Acceleration Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014732","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Therapy Evaluation Program"},{"DOI":"10.13039\/100016618","name":"Gilbert Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011221","name":"School of Medicine, University of Alabama at Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011221","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neurofibromatosis Type 1 (NF1) is caused by loss of function variants in the <jats:italic>NF1<\/jats:italic> gene. Most patients with NF1 develop skin lesions called cutaneous neurofibromas (cNFs). Currently the only approved therapeutic for NF1 is selumetinib, a mitogen -activated protein kinase (MEK) inhibitor. The purpose of this study was to analyze the transcriptome of cNF tumors before and on selumetinib treatment to understand both tumor composition and response. We obtained biopsy sets of tumors both pre- and on- selumetinib treatment from the same individuals and were able to collect sets from four separate individuals. We sequenced mRNA from 5844 nuclei and identified 30,442 genes in the untreated group and sequenced 5701 nuclei and identified 30,127 genes in the selumetinib treated group. We identified and quantified distinct populations of cells (Schwann cells, fibroblasts, pericytes, myeloid cells, melanocytes, keratinocytes, and two populations of endothelial cells). While we anticipated that cell proportions might change with treatment, we did not identify any one cell population that changed significantly, likely due to an inherent level of variability between tumors. We also evaluated differential gene expression based on drug treatment in each cell type. Ingenuity pathway analysis (IPA) was also used to identify pathways that differ on treatment. As anticipated, we identified a significant decrease in ERK\/MAPK signaling in cells including Schwann cells but most specifically in myeloid cells. Interestingly, there is a significant decrease in opioid signaling in myeloid and endothelial cells; this downward trend is also observed in Schwann cells and fibroblasts. Cell communication was assessed by RNA velocity, Scriabin, and CellChat analyses which indicated that Schwann cells and fibroblasts have dramatically altered cell states defined by specific gene expression signatures following treatment (RNA velocity). There are dramatic changes in receptor-ligand pairs following treatment (Scriabin), and robust intercellular signaling between virtually all cell types associated with extracellular matrix (ECM) pathways (Collagen, Laminin, Fibronectin, and Nectin) is downregulated after treatment. These response specific gene signatures and interaction pathways could provide clues for understanding treatment outcomes or inform future therapies.<\/jats:p>","DOI":"10.1186\/s40478-024-01821-z","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T04:02:11Z","timestamp":1718942531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response"],"prefix":"10.1186","volume":"12","author":[{"given":"Cameron","family":"Church","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian X.","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Kriukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren Ashley","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Korf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret R.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte C.","family":"Widemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kesterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Baranov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8217-0892","authenticated-orcid":false,"given":"Deeann","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"issue":"1","key":"1821_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8","volume":"89","author":"JM Friedman","year":"1999","unstructured":"Friedman JM (1999) Epidemiology of neurofibromatosis type 1. Am J Med Genet 89(1):1\u20136","journal-title":"Am J Med Genet"},{"issue":"5","key":"1821_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrc3911","volume":"15","author":"N Ratner","year":"2015","unstructured":"Ratner N, Miller SJ (2015) A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer 15(5):290\u2013301","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1821_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1542\/peds.2007-3204","volume":"123","author":"VC Williams","year":"2009","unstructured":"Williams VC et al (2009) Neurofibromatosis type 1 revisited. Pediatrics 123(1):124\u2013133","journal-title":"Pediatrics"},{"issue":"Suppl 1","key":"1821_CR4","first-page":"i107","volume":"2","author":"BH Chamseddin","year":"2020","unstructured":"Chamseddin BH, Le LQ (2020) Management of cutaneous neurofibroma: current therapy and future directions. Neurooncol Adv 2(Suppl 1):i107\u2013i116","journal-title":"Neurooncol Adv"},{"issue":"6","key":"1821_CR5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/00000637-199106000-00016","volume":"26","author":"DW Becker Jr","year":"1991","unstructured":"Becker DW Jr (1991) Use of the carbon dioxide laser in treating multiple cutaneous neurofibromas. Ann Plast Surg 26(6):582\u2013586","journal-title":"Ann Plast Surg"},{"issue":"6","key":"1821_CR6","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/brain\/111.6.1355","volume":"111","author":"SM Huson","year":"1988","unstructured":"Huson SM, Harper PS, Compston DA (1988) Von Recklinghausen neurofibromatosis: A clinical and population study in south-east Wales. Brain 111(6):1355\u20131381","journal-title":"Brain"},{"issue":"12","key":"1821_CR7","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/s41416-018-0073-2","volume":"118","author":"RJ Allaway","year":"2018","unstructured":"Allaway RJ et al (2018) Cutaneous neurofibromas in the genomics era: current understanding and open questions. Br J Cancer 118(12):1539\u20131548","journal-title":"Br J Cancer"},{"issue":"7 Suppl 1","key":"1821_CR8","first-page":"S15","volume":"97","author":"A Cannon","year":"2021","unstructured":"Cannon A et al (2021) Perspective of adults with neurofibromatosis 1 and cutaneous neurofibromas: implications for clinical trials. Neurology 97(7 Suppl 1):S15\u2013S24","journal-title":"Neurology"},{"issue":"2 Suppl 1","key":"1821_CR9","first-page":"S14","volume":"91","author":"JP Brosseau","year":"2018","unstructured":"Brosseau JP et al (2018) The biology of cutaneous neurofibromas: Consensus recommendations for setting research priorities. Neurology 91(2 Suppl 1):S14-s20","journal-title":"Neurology"},{"issue":"1","key":"1821_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40478-020-01103-4","volume":"9","author":"J-P Brosseau","year":"2021","unstructured":"Brosseau J-P et al (2021) Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing. Acta Neuropathol Commun 9(1):11","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"1821_CR11","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ajpath.2010.10.041","volume":"178","author":"EM Jouhilahti","year":"2011","unstructured":"Jouhilahti EM et al (2011) The development of cutaneous neurofibromas. Am J Pathol 178(2):500\u2013505","journal-title":"Am J Pathol"},{"key":"1821_CR12","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1749-6632.1986.tb48079.x","volume":"486","author":"J Peltonen","year":"1986","unstructured":"Peltonen J et al (1986) Collagens in neurofibromas and neurofibroma cell cultures. Ann N Y Acad Sci 486:260\u2013270","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"1821_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/BF00691316","volume":"55","author":"J Peltonen","year":"1981","unstructured":"Peltonen J et al (1981) Collagen synthesis in cells cultured from v. Recklinghausen\u2019s Neurofibromatosis Acta Neuropathol 55(3):183\u2013187","journal-title":"Recklinghausen's Neurofibromatosis Acta Neuropathol"},{"issue":"5","key":"1821_CR14","first-page":"345","volume":"92","author":"J Peltonen","year":"1984","unstructured":"Peltonen J et al (1984) Distribution of different collagen types and fibronectin in neurofibromatosis tumours. Acta Pathol Microbiol Immunol Scand A 92(5):345\u2013352","journal-title":"Acta Pathol Microbiol Immunol Scand A"},{"issue":"26","key":"1821_CR15","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi E et al (2016) Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med 375(26):2550\u20132560","journal-title":"N Engl J Med"},{"issue":"1","key":"1821_CR16","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI60578","volume":"123","author":"WJ Jessen","year":"2013","unstructured":"Jessen WJ et al (2013) MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 123(1):340\u2013347","journal-title":"J Clin Invest"},{"issue":"15","key":"1821_CR17","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross AM et al (2020) Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med 382(15):1430\u20131442","journal-title":"N Engl J Med"},{"issue":"6","key":"1821_CR18","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1158\/0008-5472.CAN-09-1577","volume":"70","author":"JR Dry","year":"2010","unstructured":"Dry JR et al (2010) Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 70(6):2264\u20132273","journal-title":"Cancer Res"},{"issue":"12","key":"1821_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI168227","volume":"133","author":"C Jiang","year":"2023","unstructured":"Jiang C et al (2023) Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor. J Clin Invest 133(12):1","journal-title":"J Clin Invest"},{"issue":"7719","key":"1821_CR20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41586-018-0414-6","volume":"560","author":"G La Manno","year":"2018","unstructured":"La Manno G et al (2018) RNA velocity of single cells. Nature 560(7719):494\u2013498","journal-title":"Nature"},{"issue":"3","key":"1821_CR21","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41587-023-01782-z","volume":"42","author":"AJ Wilk","year":"2024","unstructured":"Wilk AJ et al (2024) Comparative analysis of cell\u2013cell communication at single-cell resolution. Nat Biotechnol 42(3):470\u2013483","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1821_CR22","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S et al (2021) Inference and analysis of cell-cell communication using Cell Chat. Nat Commun 12(1):1088","journal-title":"Nat Commun"},{"key":"1821_CR23","doi-asserted-by":"crossref","unstructured":"Jin S, Plikus MV, Nie Q (2023) CellChat for systematic analysis of cell-cell communication from single-cell and spatially resolved transcriptomics. bioRxiv 2023.11.05.565674","DOI":"10.1101\/2023.11.05.565674"},{"issue":"2","key":"1821_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao Y et al (2024) Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol 42(2):293\u2013304","journal-title":"Nat Biotechnol"},{"issue":"13","key":"1821_CR25","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y et al (2021) Integrated analysis of multimodal single-cell data. Cell 184(13):3573-3587.e29","journal-title":"Cell"},{"key":"1821_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/database\/baz046","volume":"2019","author":"O Franz\u00e9n","year":"2019","unstructured":"Franz\u00e9n O, Gan L-M, Bj\u00f6rkegren JLM (2019) PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data. Database 2019:1","journal-title":"Database"},{"issue":"4","key":"1821_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kr\u00e4mer","year":"2014","unstructured":"Kr\u00e4mer A et al (2014) Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30(4):523\u2013530","journal-title":"Bioinformatics"},{"issue":"1","key":"1821_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf FA, Angerer P, Theis FJ (2018) SCANPY: large-scale single-cell gene expression data analysis. Genome Biol 19(1):15","journal-title":"Genome Biol"},{"issue":"1","key":"1821_CR29","first-page":"1","volume":"39","author":"L Faure","year":"2022","unstructured":"Faure L et al (2022) scFates: a scalable python package for advanced pseudotime and bifurcation analysis from single-cell data. Bioinformatics 39(1):1","journal-title":"Bioinformatics"},{"issue":"6","key":"1821_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098679","volume":"9","author":"M Jacomy","year":"2014","unstructured":"Jacomy M et al (2014) ForceAtlas2, a continuous graph layout algorithm for handy network visualization designed for the Gephi software. PLoS ONE 9(6):e98679","journal-title":"PLoS ONE"},{"issue":"12","key":"1821_CR31","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41587-020-0591-3","volume":"38","author":"V Bergen","year":"2020","unstructured":"Bergen V et al (2020) Generalizing RNA velocity to transient cell states through dynamical modeling. Nat Biotechnol 38(12):1408\u20131414","journal-title":"Nat Biotechnol"},{"issue":"10","key":"1821_CR32","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/labinvest.2016.88","volume":"96","author":"H Li","year":"2016","unstructured":"Li H et al (2016) Immortalization of human normal and NF1 neurofibroma Schwann cells. Lab Invest 96(10):1105\u20131115","journal-title":"Lab Invest"},{"issue":"6","key":"1821_CR33","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/S0002-9440(10)61148-0","volume":"160","author":"T Korkiam\u00e4ki","year":"2002","unstructured":"Korkiam\u00e4ki T et al (2002) Altered calcium-mediated cell signaling in keratinocytes cultured from patients with neurofibromatosis type 1. Am J Pathol 160(6):1981\u20131990","journal-title":"Am J Pathol"},{"issue":"2","key":"1821_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.2478\/v10134-010-0025-8","volume":"1","author":"Y Wang","year":"2010","unstructured":"Wang Y et al (2010) Altered calcium currents and axonal growth in Nf1 haploinsufficient mice. Transl Neurosci 1(2):106\u2013114","journal-title":"Transl Neurosci"},{"issue":"11","key":"1821_CR35","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1097\/j.pain.0000000000001026","volume":"158","author":"A Moutal","year":"2017","unstructured":"Moutal A et al (2017) Dissecting the role of the CRMP2-neurofibromin complex on pain behaviors. Pain 158(11):2203\u20132221","journal-title":"Pain"},{"issue":"1","key":"1821_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10(1):9\u201322","journal-title":"Nat Rev Cancer"},{"key":"1821_CR37","doi-asserted-by":"crossref","unstructured":"Wilk AJ, et al (2023) Comparative analysis of cell-cell communication at single-cell resolution. Nat Biotechnol","DOI":"10.1101\/2022.02.04.479209"},{"issue":"14","key":"1821_CR38","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1111\/febs.16406","volume":"289","author":"X Zhuo","year":"2022","unstructured":"Zhuo X et al (2022) The Yin-Yang roles of protease-activated receptors in inflammatory signalling and diseases. FEBS J 289(14):4000\u20134020","journal-title":"FEBS J"},{"issue":"6","key":"1821_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms19061568","volume":"19","author":"H Ungefroren","year":"2018","unstructured":"Ungefroren H et al (2018) Signaling crosstalk of TGF-\u03b2\/ALK5 and PAR2\/PAR1: a complex regulatory network controlling fibrosis and cancer. Int J Mol Sci 19(6):1","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1821_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm5120111","volume":"5","author":"D Witte","year":"2016","unstructured":"Witte D et al (2016) Proteinase-activated receptor 2 is a novel regulator of TGF-\u03b2 signaling in pancreatic cancer. J Clin Med 5(12):1","journal-title":"J Clin Med"},{"issue":"5","key":"1821_CR41","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1084\/jem.192.5.695","volume":"192","author":"MR DiChiara","year":"2000","unstructured":"DiChiara MR et al (2000) Inhibition of E-selectin gene expression by transforming growth factor beta in endothelial cells involves coactivator integration of Smad and nuclear factor kappaB-mediated signals. J Exp Med 192(5):695\u2013704","journal-title":"J Exp Med"},{"key":"1821_CR42","first-page":"S5","volume":"91","author":"N Ortonne","year":"2018","unstructured":"Ortonne N et al (2018) Cutaneous neurofibromas. Curr Clin Pathol Iss 91:S5\u2013S13","journal-title":"Curr Clin Pathol Iss"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-024-01821-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-024-01821-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-024-01821-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T20:19:36Z","timestamp":1719001176000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-024-01821-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1821"],"URL":"https:\/\/doi.org\/10.1186\/s40478-024-01821-z","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human subjects and all sample collection and use were approved by the Institutional Review Board at The University of Alabama at Birmingham and conformed to NIH guidelines. Written informed consent was obtained from patients participating in clinical trial number NCT02839720.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All financial and non-financial competing interests must be declared in this section. Bruce Korf is on medical advisory boards for Alexion, SpringWorks, Healx, Infixion, and Recursion. All other authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}